Overview

• Produce in-vitro transcribed RNA with very low dsRNA byproduct that is notably safer for in vivo administration

• Retain the same high yields as T7 RNA polymerase ver.2 (Cat. # 2541A), especially when used with cap analogs such as CleanCap Reagent AG (TriLink Bio Technologies)

• Get improved heat resistance (up to 52°C) compared to T7 RNA polymerase ver.2.0

Product Description

Trace amounts of double-stranded RNA (dsRNA) byproduct produced during in vitro transcription can interfere with downstream in vivo administration by triggering unwanted immune responses. PrimeCap T7 RNA Polymerase (low dsRNA) is a modified form of T7 RNA polymerase that combines highly efficient cap-analog-dependent RNA synthesis with extremely low dsRNA generation, making it the ideal choice for researchers engaged in mRNA therapeutic research and development.

Substance

• PrimeCap T7 RNA Polymerase, HQ (200 U/μl)　　　200,000 U
• 10× IVT Reaction Buffer, HQ　　　10 ml

Preservation

－20℃

Visit Takara Bio website : https://www.takarabio.com/products/mrna-and-cdna-synthesis/in-vitro-transcription/rna-polymerases-and-rntps/primecap-t7-rna-polymerase-(low-dsrna)